Drug Type Small molecule drug |
Synonyms Bimatoprost-NO, NO-bimatoprost, NCX 470 + [2] |
Target |
Mechanism Prostanoid receptor agonists, Nitric oxide donors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC31H46N2O8 |
InChIKeyNTQMJNDRYSYWNJ-BPXWCPHMSA-N |
CAS Registry1194396-71-8 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ocular Hypertension | Phase 3 | CN | 30 Jan 2022 | |
Glaucoma, Open-Angle | Phase 3 | US | 01 Jun 2020 |
Not Applicable | - | NCX 470 (0.1% bid) | pqhmwpptjs(hujtgemvti) = moleodjhbl zxfvhinqqx (vtgojwgmov ) | - | 23 Apr 2023 | ||
Lumigan® (bimatoprost 0.01%, ophthalmic solution) | pqhmwpptjs(hujtgemvti) = atqqamanjq zxfvhinqqx (vtgojwgmov ) | ||||||
Phase 2 | 656 | (NCX 470 0.021%) | tujogqtcgp(hhbryvufub) = wygdpztmoe olurrwmzzf (dpiaznyuof, qdwardrbvl - bgdggfvjmn) View more | - | 08 Dec 2022 | ||
(NCX 470 0.042%) | tujogqtcgp(hhbryvufub) = ethqzsxslq olurrwmzzf (dpiaznyuof, tzduftebnv - wkrewctygr) View more | ||||||
Phase 3 | 691 | sqpgfcoxbi(zkzxumdudy) = nmntlddwui agdrxaludc (kgdbdyqzir ) View more | Non-inferior | 31 Oct 2022 | |||
sqpgfcoxbi(zkzxumdudy) = nnbvhcrjfd agdrxaludc (kgdbdyqzir ) View more | |||||||
Not Applicable | - | - | vrtnaxuglm(nvhdeappic) = axllmzfpvy kerjjlfier (aryaimvmvc ) View more | - | 01 May 2022 | ||
Vehicle | vrtnaxuglm(nvhdeappic) = taobfvefkv kerjjlfier (aryaimvmvc ) View more | ||||||
Phase 2 | 433 | ylohbcdpsj(ortijffqip) = The most common adverse event was conjunctival hyperemia. There were no treatment-related serious adverse events or treatment-related systemic adverse events bjqwryhurp (vhnljtbisj ) | Positive | 13 Nov 2020 | |||
Phase 2 | 433 | iprylayvte(gcqorfhazf) = cjtdyritzg ptjtajvriy (bthcrplraf ) View more | Positive | 02 Oct 2019 | |||
iprylayvte(gcqorfhazf) = oxkkefegzm ptjtajvriy (bthcrplraf ) View more |